Complete blood count analysis was evaluated in each blood sample using the hematology analyzer Mythic 18 (C2 Diagnostics, Montpellier, France).
Supplementary
. Calcitriol, PRI-2191, and PRI-2205 increased lymphocyte and monocyte percentage with a parallel decrease in granulocytes percentage in mice bearing 4T1 mammary gland tumors.
(A) General white blood cell count (WBC); the number (B) and the percentage (C) of: lymphocytes, (D) and (E) monocytes, (F) and (G) granulocytes. From day 7, vitamin D analogs were administered subcutaneously (s.c.) thrice a week. The single dose of compounds was as follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg. Number of mice was 9-12 per group. The blood morphology was evaluated in each blood sample using the Mythic 18 automatic analyzer. Data are presented as mean ± SD. Statistical analysis: KruskalWallis multiple comparison test. *p<0.05.
Supplementary Figure S2. Selected blood morphological parameters of mice bearing 4T1 mammary gland tumors and treated with calcitriol and its analogs: PRI-2191 and PRI-2205.
(A) Erythrocytes number; (B) hemoglobin (Hb); (C) hematocrit; (D) mean cell volume (MCV); (E) mean corpuscular hemoglobin (MCH); (F) mean corpuscular hemoglobin concentration (MCHC); (G) red distribution width (RDW); (H) platelets number. Mice were inoculated orthotopically with 4T1 cells on day 0. From day 7 (7 days after tumor inoculation), vitamin D analogs were administered subcutaneously (s.c.) thrice a week. The single dose of compounds were as follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg. Number of mice were 6 per group. Data are presented as mean with standard deviation. Statistical analysis: Kruskal-Wallis multiple comparison test. *P<0.05 as compare to control mice on appropriate day or as indicated.
Supplementary Figure S3. Selected cytokine levels in plasma and supernatants from lipopolisaccharide (LPS)-or Concanavalin A (ConA)-stimulated splenocytes.
Supernatants obtained from spleen cells (harvested on days 14 and 28) stimulated with LPS (A) and ConA (B). Plasma from mice harvested on days 14 or 21 and 28 or 33 (C). Samples were analyzed with ELISA tests. Number of samples analyzed was 2-6 per group. Data are presented as mean ± SD and individual sample results. Statistical analysis: Kruskal-Wallis multiple comparison test. *p<0.05.
Supplementary Figure S4 . Expression of selected cytokines in tumor tissue. Real-time PCR analysis of four selected genes. (A) Ceruloplasmin (Cp), (B) Coagulation factor II, thrombin (F2), (C) Fibrinogen alpha chain (Fga), and (D) Serum amyloid A (Saa). Real-time PCR reaction was performed using specific primers coding following genes: Cp (Mm01289313_m1), F2 (Mm00438843_m1), Fga (Mm00802584_m1), and Saa (Mm04208126_m1). Briefly, 50 ng of cDNA was used for a single reaction and each sample was performed in triplicate in a single experiment. Data were analyzed using comparative ΔΔCt method by DataAssist 3.01 software in comparison to endogenous control: hypoxanthine phosphoribosyltransferase 1 (Hprt1, Mm00446968_m1). Mice were orthotopically inoculated with 4T1 cells on day 0. From day 7 (7 days after tumor inoculation), vitamin D analogs were administered subcutaneously (s.c.) thrice a week. A single dose of compounds were as follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg. Number of mice: 9-12 per group. Data are presented as mean ± SD. Tables   Table S1 . The fold change values of genes associated with precursor T cells differentiation in splenocytes samples from 4T1 tumor bearing mice treated with calcitriol or its analogs. Mouse T Helper Cell Differentiation RT 2 Profiler Array (Qiagen, Hilden, Germany) including 84 key genes and 5 housekeeping genes in the set. Data shows a mean relative quantification (RQ) values. Fold-change (RQ) of target genes was defined using double delta Ct method in reference to actin, beta (Actb) and beta-2 microglobulin (B2m) for splenocytes samples. Then the results were adjusted to the values obtained for the control group within the day 21 or 28 th of the experiment for each treatment group. Data analysis was acquired using Qiagen online software suitable for purchased kit (Qiagen, Hilden, Germany). PCR amplification cycles were as follows 95 °C for 10 s and 58 °C for 45 s (50 cycles). We used 0,5 µg of cDNA (6 mice pooled per group) for a single reaction. (Table S1 ). Data presented as a mean relative quantification (RQ) values. Foldchange (RQ) of target cDNA was defined using double delta Ct method in reference to beta-2 microglobulin (B2m), glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and heat shock protein 90 alpha, class B member 1 (Hsp90ab1). Next the results were adjusted to the values obtained for the control group within the day 14 or 28 th of the experiment for each treatment group. Data analysis was acquired using Qiagen online software suitable for purchased kit (Qiagen. Hilden. Germany). PCR amplification cycles were as follows 95 °C for 10 s and 58 °C for 45 s (50 cycles). We used 0.5 µg of cDNA (6 mice pooled per group) for a single reaction. Lung specimens were collected on the days 14 and 28 (after inoculation with 4T1 cells) from mice treated with calcitriol or its analogs and control group receiving vehicle. Real-time PCR screening was performed using the mouse tumor invasion/metastasis PCR array library (MTIM-1). From 88 genes available in this array (Table S2) the expression for 45 genes was not detected in 4T1 lung tissue. Data presented as a mean relative quantification (RQ) values (calculated from duplicate). Fold-change (RQ) of target cDNA was determined by calculating the differences in ΔΔCT values in reference to ribosomal protein L13A (Rpl13a) and adjusted to the values obtained for the untreated mice (named D0) for each treatment group. Data analysis was performed by DataAssist v 3.01 software. All PCR amplification cycles were performed at 95 °C for 10 s and 58 °C for 45 s (50 cycles). We used 25 ng of cDNA for a single reaction and each test was performed in duplicate. Signal transducer and activator of transcription 6 Tbx21 T-box 21 Tgif1 TGFB-induced factor homeobox 1 Tlr4
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Toll-like receptor 4 Tlr6
Toll-like receptor 6 Tmed1
Transmembrane emp24 domain containing 1 Tnf Tumor necrosis factor Tnfrsf9
Tumor necrosis factor receptor superfamily, member 9 Tnfsf11
Tumor necrosis factor (ligand) superfamily, member 11 Trp53inp1 Transformation related protein 53 inducible nuclear protein 1
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